Fox Run Management L.L.C. Makes New $1 Million Investment in Glaukos Corporation $GKOS

Fox Run Management L.L.C. acquired a new stake in Glaukos Corporation (NYSE:GKOS) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 12,308 shares of the medical instruments supplier’s stock, valued at approximately $1,004,000.

Other institutional investors have also recently modified their holdings of the company. UMB Bank n.a. increased its position in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the period. REAP Financial Group LLC acquired a new stake in Glaukos during the third quarter worth about $40,000. AlphaQuest LLC increased its holdings in Glaukos by 5,754.5% in the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 633 shares during the period. SBI Securities Co. Ltd. increased its holdings in Glaukos by 42.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after buying an additional 362 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GKOS. Needham & Company LLC increased their price target on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Stifel Nicolaus raised their target price on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. UBS Group lifted their price target on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Truist Financial boosted their price target on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 price objective on shares of Glaukos in a research note on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Stock Up 0.6%

Shares of GKOS opened at $121.62 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $130.23. The stock has a market capitalization of $7.06 billion, a price-to-earnings ratio of -37.31 and a beta of 0.70. The stock has a fifty day moving average of $115.92 and a 200-day moving average of $99.78.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company’s revenue was up 35.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.40) EPS. As a group, sell-side analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the transaction, the director owned 34,905 shares in the company, valued at $3,744,259.35. This trade represents a 12.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of Glaukos stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the sale, the director owned 18,806 shares in the company, valued at approximately $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 325,000 shares of company stock valued at $37,739,259 over the last three months. Insiders own 5.80% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.